M6A RNA methylation modification and tumor immune microenvironment in lung adenocarcinoma

Shujuan Li; Qianzhong Li; Luqiang Zhang; Yechen Qi; Hui Bai

doi:10.52601/bpr.2023.220020

Volume 9 Issue 3

Jun. 2023

Turn off MathJax

Article Contents

Article Navigation > Biophysics Reports > 2023 > 9(3): 146-158

Shujuan Li, Qianzhong Li, Luqiang Zhang, Yechen Qi, Hui Bai. M6A RNA methylation modification and tumor immune microenvironment in lung adenocarcinoma. Biophysics Reports, 2023, 9(3): 146-158. doi: 10.52601/bpr.2023.220020

Citation:

Shujuan Li, Qianzhong Li, Luqiang Zhang, Yechen Qi, Hui Bai. M6A RNA methylation modification and tumor immune microenvironment in lung adenocarcinoma. Biophysics Reports, 2023, 9(3): 146-158. doi: 10.52601/bpr.2023.220020

Citation:

PDF (7567 KB)

M6A RNA methylation modification and tumor immune microenvironment in lung adenocarcinoma

doi: 10.52601/bpr.2023.220020

1.
Laboratory of Theoretical Biophysics, School of Physical Science and Technology, Inner Mongolia University, Hohhot 010021, China
2.
The State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, Inner Mongolia University, Hohhot 010070, China

More Information

Corresponding author: qzli@imu.edu.cn (Q. Li)
Received Date: 22 August 2022
Accepted Date: 30 May 2023

Available Online: 07 June 2023

Publish Date: 01 June 2023

Abstract

Abstract

Lung adenocarcinoma is one of the deadliest tumors. Studies have shown that N6-methyladenosine RNA methylation regulators, as a dynamic chemical modification, affect the occurrence and development of lung adenocarcinoma. To investigate the relationship between mutations and expression levels of m6A regulators in lung adenocarcinoma, we investigated the mutations and expression levels of 38 m6A regulators. We found that mutations in m6A regulatory factors did not affect the changes in expression levels, and 19 differentially expressed genes were identified. All tumor samples were classified into two subtypes based on the expression levels of 19 differentially expressed m6A-regulated genes. Survival analysis showed significant differences in survival between the two subtypes. To explore the relationship between immune cell infiltration and survival in both subtypes, we calculated the infiltration of 23 immune cells in both subtypes, and we found that the subtype with high immune cell infiltration had better survival. We found that subtypes with low tumor purity and high stromal and immune scores had better survival. The m6A-related immune genes were identified by taking the intersection of differentially expressed genes and immune genes in the two isoforms and calculating the Pearson correlation coefficients between the intersecting immune genes and the differentially expressed m6A-regulated genes. Finally, a prognostic model associated with m6A and associated with immunity was developed using prognostic genes screened from m6A-associated immune genes. The predictive power of the model was evaluated and our model was able to achieve good prediction.
- Lung adenocarcinoma,
- M6A RNA methylation regulators,
- Consensus clustering,
- Immune cell infiltrates,
- Tumor immune microenvironment

Shujuan Li, Qianzhong Li, Luqiang Zhang, Yechen Qi and Hui Bai declare that they have no conflict of interest.
This article does not contain any studies with human or animal subjects performed by any of the authors.

FullText(HTML)

References(35)

References

Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V (2019) The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer 19: 9−31 doi: 10.1038/s41568-018-0081-9

Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P (2020) Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 18: 59. https://doi.org/10.1186/s12964-020-0530-4

Bai H, Li QZ, Qi YC, Zhai YY, Jin W (2022) The prediction of tumor and normal tissues based on the DNA methylation values of ten key sites. Biochim Biophys Acta Gene Regul Mech 1865: 194841. https://doi.org/10.1016/j.bbagrm.2022.194841

Barbieri I, Kouzarides T (2020) Role of RNA modifications in cancer. Nat Rev Cancer 20: 303−322 doi: 10.1038/s41568-020-0253-2

Chen J, Gao G, Li L, Ding J, Chen X, Lei J, Long H, Wu L, Long X, He L, Shen Y, Yang J, Lu Y, Sun Y (2022) Pan-cancer study of SHC-adaptor protein 1 (SHC1) as a diagnostic, prognostic and immunological biomarker in human cancer. Front Genet 13: 817118. https://doi.org/10.3389/fgene.2022.817118

Denisenko TV, Budkevich IN, Zhivotovsky B (2018) Cell death-based treatment of lung adenocarcinoma. Cell Death Dis 9: 117. https://doi.org/10.1038/s41419-017-0063-y

Ding Y, Qi N, Wang K, Huang Y, Liao J, Wang H, Tan A, Liu L, Zhang Z, Li J, Kong J, Qin S, Jiang Y (2020) FTO facilitates lung adenocarcinoma cell progression by activating cell migration through mRNA demethylation. Onco Targets Ther 13: 1461−1470 doi: 10.2147/OTT.S231914

Do HTT, Lee CH, Cho J (2020) Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel) 12: 287. https://doi.org/10.3390/cancers12020287

Dolly SO, Collins DC, Sundar R, Popat S, Yap TA (2017) Advances in the development of molecularly targeted agents in non-small-cell lung cancer. Drugs 77(8): 813−827 doi: 10.1007/s40265-017-0732-2

Fang J, Hu M, Sun Y, Zhou S, Li H (2020) Expression profile analysis of m6A RNA methylation regulators indicates they are immune signature associated and can predict survival in kidney renal cell carcinoma. DNA Cell Biol. https://doi.org/10.1089/dna.2020.5767

Fatai AA, Gamieldien J (2018) A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer. BMC Cancer 18: 377. https://doi.org/10.1186/s12885-018-4103-5

Feng ZX, Li QZ, Meng JJ (2019) Modeling the relationship of diverse genomic signatures to gene expression levels with the regulation of long-range enhancer-promoter interactions. Biophysics Reports 5: 123−132 doi: 10.1007/s41048-019-0089-z

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960−1964 doi: 10.1126/science.1129139

Galon J, Fridman WH, Pagès F (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67: 1883−1886 doi: 10.1158/0008-5472.CAN-06-4806

Guo X, Liu Y, Liu LJ, Li J, Zhao L, Jin XR, Yan W, Lin BQ, Shi S, Li ZY, Wang S, Wu X, Chen HY, Shen Y, Wei YW (2021) Development and validation of survival nomograms in colorectal cancer patients with synchronous liver metastases underwent simultaneous surgical treatment of primary and metastatic lesions. Am J Cancer Res 11: 2654−2669

Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309−322 doi: 10.1016/j.ccr.2012.02.022

Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Jr., Wu YL, Paz-Ares L (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389: 299−311 doi: 10.1016/S0140-6736(16)30958-8

Hu M, Polyak K (2008) Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18: 27−34 doi: 10.1016/j.gde.2007.12.006

Khan RIN, Malla WA (2021) m(6)A modification of RNA and its role in cancer, with a special focus on lung cancer. Genomics 113: 2860−2869 doi: 10.1016/j.ygeno.2021.06.013

Kobayashi M, Nagashio R, Saito K, Aguilar-Bonavides C, Ryuge S, Katono K, Igawa S, Tsuchiya B, Jiang SX, Ichinoe M, Murakumo Y, Saegusa M, Satoh Y, Sato Y (2018) Prognostic significance of S100A16 subcellular localization in lung adenocarcinoma. Hum Pathol 74: 148−155 doi: 10.1016/j.humpath.2018.01.001

Li M, Zha X, Wang S (2021) The role of N6-methyladenosine mRNA in the tumor microenvironment. Biochim Biophys Acta Rev Cancer 1875: 188522. https://doi.org/10.1016/j.bbcan.2021

Ma L, Chen T, Zhang X, Miao Y, Tian X, Yu K, Xu X, Niu Y, Guo S, Zhang C, Qiu S, Qiao Y, Fang W, Du L, Yu Y, Wang J (2021) The m(6)A reader YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing SLC7A11-dependent antioxidant function. Redox Biol 38: 101801. https://doi.org/10.1016/j.redox.2020.101801

Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654−2666 doi: 10.1056/NEJMoa051424

Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19: 1423−1437 doi: 10.1038/nm.3394

Shulman Z, Stern-Ginossar N (2020) The RNA modification N(6)-methyladenosine as a novel regulator of the immune system. Nat Immunol 21: 501−512

Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72: 7−33 doi: 10.3322/caac.21708

Song P, Zhao F, Li D, Qu J, Yao M, Su Y, Wang H, Zhou M, Wang Y, Gao Y, Li F, Zhao D, Zhang F, Rao Y, Xia M, Li H, Wang J, Cheng M (2022) Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells. Acta Pharm Sin B 12: 2905−2922 doi: 10.1016/j.apsb.2022.02.029

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545−15550 doi: 10.1073/pnas.0506580102

Sun T, Wu R, Ming L (2019) The role of m6A RNA methylation in cancer. Biomed Pharmacother 112: 108613. https://doi.org/10.1016/j.biopha.2019

Xu Y, Lv D, Yan C, Su H, Zhang X, Shi Y, Ying K (2022) METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m(6)A modification. Cancer Cell Int 22: 11. https://doi.org/10.1186/s12935-021-02433-6

Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4: 2612. https://doi.org/10.1038/ncomms3612

Zaccara S, Ries RJ, Jaffrey SR (2019) Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol 20: 608−624 doi: 10.1038/s41580-019-0168-5

Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL (2020a) m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer 19: 53. https://doi.org/10.1186/s12943-020-01170-0

Zhang Q, Wang W, Zhou Q, Chen C, Yuan W, Liu J, Li X, Sun Z (2020b) Roles of circRNAs in the tumour microenvironment. Mol Cancer 19: 14. https://doi.org/10.1186/s12943-019-1125-9

Zhang Z, Zhang C, Luo Y, Wu P, Zhang G, Zeng Q, Wang L, Yang Z, Xue L, Zheng B, Zeng H, Tan F, Xue Q, Gao S, Sun N, He J (2021) m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer. BMC Med 19: 284. https://doi.org/10.1186/s12916-021-02148-5

Supplements(1)